United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

american health packaging - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

app pharmaceuticals, llc - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole 2.5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials).,the safety and efficacy of neoadjuvant use of letrozole has not been established.,letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; microcrystalline cellulose; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - letrozole 2.5mg - film coated tablet - 2.5 mg - active: letrozole 2.5mg excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate opadry yellow 03f92493 povidone